Table 1.
Baseline characteristics of study participants.
Figure 1.
Platelet-monocyte aggregate formation in IPF patients and controls.
A. Scatter plot demonstrating the different cell populations on whole blood flow cytometry, gated on monocytes. B. Quadrant plot demonstrating platelet-monocyte aggregates in the right upper quadrant. X-axis (FL1) shows CD42b staining and y-axis (FL2) shows CD14 staining. C. Percentage of monocytes forming aggregates with platelets at basal levels and in response to the platelet agonists ADP (0.1–10 µM) or TFLLR (1–10 µM). * P≤0.01.
Figure 2.
Percentage of monocytes forming aggregates with platelets in the presence of 1 mM EDTA under basal conditions and when stimulated with ADP (0.1–10 µM) or TFLLR (1–10 µM) in subjects with IPF and controls.
Figure 3.
Platelet P-selectin expression in IPF patients and controls.
A. Representative flow cytometry histogram demonstrating platelet P-selectin expression under basal (unstimulated) conditions. B. Flow cytometry histogram demonstrating platelet P-selectin expression following stimulation with 10 µM ADP. C. Percentage of platelets expressing P-selectin at basal levels and in response to the platelet agonists ADP (0.1–10 µM) or TFLLR (1–10 µM). † P<0.05, * P≤0.01.
Figure 4.
Platelet fibrinogen binding in IPF patients and controls.
A. Representative flow cytometry histogram demonstrating platelet fibrinogen binding under basal (unstimulated) conditions. B. Flow cytometry histogram demonstrating platelet fibrinogen binding following stimulation with 10 µM ADP. C. Percentage of platelets binding fibrinogen at basal levels and in response to the platelet agonists ADP (0.1–10 µM) or TFLLR (1–10 µM). * P≤0.01.
Figure 5.
The influence of the plasma environment on platelet function in IPF patients.
Scatter plots (A,C,E,G) demonstrating platelet P-selectin expression (bars indicate means) and line graphs (B,D,F,H) showing the change in P-selectin expression of control platelets following incubation in autologous plasma, allogeneic control plasma, and IPF patient plasma at basal levels (A,B) and following stimulation with ADP 0.1 µM (C,D), 1 µM (E,F) and 10 µM (G,H).